Perrigo Company Plc Ireland (PRGO) Quote

Just got its over the counter birth control FDA approved a half hour ago !!!

Thanks PRGO

41.75 afterhours purchase

afterhours purchase above the high of the day

Why would this company invest in Kazmira?

Dividend helps starboard, but hurts the rest of the shareholders.....nobody is in this for a dividend! We want growth and profits

***NEWS OUT***

http://ih.advfn.com/p.php?pid=nmona&article=75174311&symbol=PRGO

Perrigo Launches The Generic Version Of Axiron® Topical Solution

DUBLIN, July 5, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the prescription pharmaceutical launch of testosterone topical solution, 30 mg/1.5 mL (CIII), the generic equivalent to Eli Lilly and Company's Axiron® Topical Solution, 30 mg/1.5 mL (CIII).

Axiron® Topical Solution, 30 mg/1.5 mL (testosterone topical solution, 30 mg/1.5 mL) is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for the 12 months ending April 2017 were approximately $248 million.

Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This is our third new product launch in the last two weeks. These new product launches illustrate our continued focus on developing and bringing to market important treatments in prescription extended topical therapeutic categories. The Rx team remains committed to investing in complex topical products and to launching more than five new products by the end of 2017."

About Perrigo

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world's largest manufacturer of over-the-counter ("OTC") healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com).

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to our restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and our ability to realize the desired benefits thereof; our ability to achieve our guidance; our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives; and the timing and expense to complete the announced tender offer for certain of our outstanding notes. In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2016, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

I came in @.656 on the 24th...

One month later...

NICE!

You can't ask for a nicer progression upward!

Chart:

Indicators poised for the next leg up...

PRGO...

catching her breath...

Up... up... up...

Nice rise from .656 !!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130821920

This is the kind of price action one likes to see...

slow and steady, with a little taken off the top from time to time...

and then...

reestablishing the climb...

NICE!

Best Dividend Paid in Over a Dozen Years!

http://ih.advfn.com/p.php?pid=nmona&article=74489043&symbol=PRGO

Nice, steady, upward movement for PRGO!

The stock has traded between $111.00 and $65.47 over the last 52-weeks, its 50-day SMA is now $72.19, and its 200-day SMA $83.38. Perrigo Company plc has a P/B ratio of 1.12

8-k Out

http://ih.advfn.com/p.php?pid=nmona&article=74417839&symbol=PRGO

Item of interest:

On April 7, 2017, the Company issued a notice of redemption to redeem all of the $600.0 million in aggregate principal amount of the outstanding 2.300% senior notes due 2018 (the “2.300% 2018 Notes”). The Company expects to redeem all of the 2.300% 2018 Notes on May 8, 2017 using proceeds from the sale of Tysabri

Perrigo Reaches Agreement With Auditor Over Royalty Accounting
Dublin drugmaker to restate financial statements as far back as Dec. 28, 2013

https://www.wsj.com/articles/perrigo-reaches-agreement-with-auditor-over-royalty-accounting-1493167564

Nice Timing!

**SMILES**

Daily volume doubling yesterday and already today...

Something in the works???

Nice upward movement in the past 2 days!

I came in @.656 on the 24th...

Let's see where this goes...

At a more than 50% discount, PRGO looks quite appetizing.

Anything new to get excited about?

IS Perrigo still, in your opinion, a buyout candidate, or perhaps, would they consider another alternative if their conditions cannot be met?

Anything in the wind?

*SNIFF* *SNIFF*

PRGO moving upward slowly...

3 Month PRGO Chart

Looking up...

Facebook Inc (NASDAQ:FB) Introduces New ‘Dislike’ Reaction Button On Messenger https://marketexclusive.com/facebook-inc-nasdaqfb-introduces-reaction-button-feature-messenger/79228/?icd1

Try Peregrine $PPHM. Avid Bioservices can even make biosimilars for you....




wook

This has been a welcomed couple of days. I've owned this since 2011 and will continue to own this through at least the next couple of years.

GSK consumer unit off the table it appears - http://www.telegraph.co.uk/business/2016/09/20/glaxosmithkline-names-emma-walmsley-to-replace-sir-andrew-witty/

Perrigo is becoming the Best viable option for several companies to acquire if they wish to expand in the US generics category.

We should get some meaningful news with PRGO soon


LONG PRGO.

PRGO - I'm buying the Rumor here, and settling in for the Long Haul

Van

PRGO - Reckitt Benckiser Buyout Potential


Pretty quiet here for a company that may get bought anytime....literally any Day. The puzzle pieces are fitting together way too well to be just a coincidence.


Timeline:

Back in 2015 Mylan tried to go hostile for Perrigo at a $180+ price tag, but did not succeed.

June of 2016 - Rumor hits the street of a Mystery UK buyer for PRGO at the $20B level.

July of 2016 - Rumor hits again that the UK buyer is Reckitt Benckiser of the UK, and preparing a $20B offer.

September 11th 2016 - Activist Starboard Value LP takes a 4.6% stake in PRGO, Advocating several actions within the company to Unlock Shareholder value.


Reckitt Benckiser has publicly looked at buying both Merek's Consumer health division, and Pfizer's Consumer division, but both of these are now off the table. Merek's sold to Bayer, and Pfizer is not breaking up the company until at least 2018. The Pfizer news just came out 6-days ago, so until then BR may have been waiting to see if that was a Viable option. Now it is not. There are far Fewer matches for RB now, than were possibly on the Table in 2014-2015. The clock is ticking for RB to make a move, and I think that they may make a bid for Perrigo before the new year.

My guess is RB has been kicking the Tires on Perrgio now for several months (since at least June), and waiting to see where the Dust settled on the Pfizer Breakup. RB was also mentioned as a buyer for Church & Dwight this Mayy, but those Rumors were Denied by Church & Dwight.

The last Rumor in June of this year even stated the financial Firms advising both PRGO and RB. This Seems awfully specific for an unfounded Rumor, and the June Rumor actually supports the RB theory, and the July story as well. Both Reckitt and Perrigo did NOT deny these Rumors.

Last month, a report claimed Perrigo was close to an agreement to be bought by a UK-based company for $US20bn, although it did not name the latter.

The report in StreetInsider.com cited a source as saying Morgan Stanley (NYSE:MS) was advising Perrigo and Barclays PLC (LON:BARC) was among institutions advising the UK company.


Reckitt Benckiser has been on the Acquisition hunt since at least 2014 to expand their Consumer Health division. They have not Purchased anything yet that fulfills that Goal.

RB CEO:
RB’s net debt ratio of 0.7 times adjusted earnings before interest, tax, depreciation and amortization is below that of competitors Unilever at 1.1 and Procter & Gamble Co. at 1.3, meaning the company has financial flexibility to pursue transformational acquisitions. Discussing firepower, Kapoor said that RB is not thinking about limitations on the size of a potential deal.

“If any of the interesting consumer-health assets were to come up today, I believe RB has the capacity to do it. Any of them,” he said.


With PRGO stock trading at $93 from a High of $200, with a shareholder base that is Angry regarding the slump in Stock Value, Perrigo is Ripe for a takeover bid in the $135-$160 range. The Rumor articles state that Perrigo is looking for a minimum of a 100% premium, but I don't believe if RB or another acquirer made their offer Public, it would take that elevated Premium to get it accomplished. With Starboard coming on board in the past 3-weeks, the Board and newer CEO will be under tremendous pressure to get the Share Price UP, and seriously consider any/all Major moves that may be good for the Stock Price.


Option Volume has been slightly unusual 3 days the past week, with Call Volume above normal, and directionally Bullish Action.

I continue to Add the Nov and Jan PRGO call options, along with the PRGO common stock which is Cheap whether the Perrigo Buyout with Reckitt occurs or not.

LONG PRGO !!!!!!!!!


Links:

http://www.fiercepharma.com/pharma/perrigo-up-for-20b-sale-to-mystery-u-k-buyer-report

http://www.proactiveinvestors.com/companies/news/128264/reckitt-benckiser-set-to-bid-for-perrigo-rumours-128264.html

http://www.modernhealthcare.com/article/20160926/NEWS/160929928

http://www.bloomberg.com/news/articles/2015-12-04/reckitt-benckiser-ceo-would-look-at-buying-pfizer-consumer-unit

http://www.fiercepharma.com/m-a/reckitt-benckiser-gives-up-on-merck-otc-deal-leaving-bayer-open-shot


http://www.cnbc.com/2016/05/19/church-dwight-shares-spike-amid-report-of-reckitt-benckiser-takeover-bid.html

http://thefly.com/news.php?symbol=PRGO


http://247wallst.com/healthcare-business/2015/06/01/3-specialty-pharma-stocks-that-could-be-acquired-in-2015/

Pfizer Drops plan to Breakup Company - PRGO on Deck for Reckitt

With Pfizer announcing plans that they will no longer breakup their Consumer Health division, another viable option for Reckitt has been taken off the table. My guess is they have been kicking the tires on both options for several months. In my estimation, there are fewer and fewer Consumer Health Divisions that fit the bill that Benckiser is looking to acquire.

This move may entice them to act, now that the other Potential target is off the table until at least 2018.

PRGO is in the Cross-hairs for them IMO :)

See Below.


http://www.iol.co.za/business/international/pfizer-drops-plan-to-break-up-company-2073247

http://www.bloomberg.com/news/articles/2015-12-04/reckitt-benckiser-ceo-would-look-at-buying-pfizer-consumer-unit

PRGO - I believe we get Big News here within a couple weeks. The UK buyer rumor is True in my Mind. Loading Call Options for Nov-Jan for a Big move UP. Options are trading TOO CHEAP for the buyout potential here.

Pretty Quiet on the Web about this stock.....I am surprised by that.

Van

I'm adding PRGO here. The stock is undervalued, and I believe the Takeover chatter from June and July is legitimate. The time for a buyer to strike is now while the stock is cheap, and the sector is experiencing major consolidation. A Perrigo Buyout is definitely a possibility. Reckitt Benckiser seems like a Good guess in my mind, as they have been on the Hunt for months, and picked up nothing major. Perrigo is a good fit for Reckitt

With Starboard taking a stake here, I think PRGO will have positive news within the next 4-weeks either way. They will make the BOD and Directors Unlock the True value of Perrigo. Adding PRGO Call Options and Perrigo Stock Daily.


Van

Reaction??

Interesting here :)

Nuts... High book value and earnings and fantasy for big bid to be sold to a great player
Tztztz...

Thanks

For you the same, did my "steals" yesterday,

Cheers

Always very quiet here only 20 posts in last 4 years

Seems like a great entry point at this level, pretty much at 2012/2013 lows and close to 50% off 52 week high.

I would say Up is the only direction to go from here as IMO selling was way overdone & really no major "issues".

Best to you. dp

Very silent here,
people waiting for better prices or a new offer to take from
a other pharma leading company

Valued 8times earnings, middel should be 20times,
Intersting weeks coming up, paying a div.

Touch down. ;-()

Brought some 100,45

Rebound is not far away and maybe some buy out stories in the
Coming weeks

Certainly looks that way lol looks like it was settling then the west coast effect took it down another $3 lol.

Going to zero

Wow, heading under $100?

why the big drop past days?

MYL commences tender offer for PRGO: #msg-116951856.

MYL shareholder vote on PRGO deal scheduled for 8/28/15:

http://finance.yahoo.com/news/mylan-announces-meeting-date-record-195800002.html